Mounjaro and Birth Defects: What the Evidence Shows

Step 1: understanding what the data do and do not show

Reproductive toxicology studies in animals form the evidence base here, because pregnant women were excluded from Mounjaro's clinical trials. In those animal studies, tirzepatide caused embryo-fetal toxicity — including reduced fetal growth and skeletal changes — at doses that also caused significant maternal weight loss. Crucially, it is difficult to separate a direct drug effect on the fetus from the downstream consequences of severe caloric restriction in the mother. That distinction matters scientifically, but from a safety standpoint, the outcome is the same: the risk cannot be dismissed.

No human data exist from controlled trials. This is not reassuring silence; it reflects the ethical impossibility of running pregnancy trials with a medicine where harm in animals has already been observed. The Mounjaro Summary of Product Characteristics, published on the electronic Medicines Compendium, states clearly that tirzepatide should not be used during pregnancy. The NHS medicines page for tirzepatide echoes this, advising women to tell their doctor if they are pregnant or planning a pregnancy before starting treatment.

In practice, a question our prescribers hear most weeks is whether it is safe to stay on Mounjaro once a pregnancy is confirmed. The short answer is no. The appropriate step is to stop tirzepatide straight away and contact your GP or maternity team. Post-marketing surveillance will build a clearer human picture over time, but current guidance is unambiguous.

Step 2: stopping Mounjaro before trying to conceive

Because tirzepatide has a long half-life, it remains pharmacologically active in the body for some time after the last dose. UK clinical guidance advises stopping the medicine before attempting conception, allowing a washout period. The exact window your prescriber recommends will depend on your individual circumstances; the Mounjaro Patient Information Leaflet and your clinical team are the right sources for that figure, not body copy on a website.

The NHS England weight-management injections guidance addresses this point directly, noting that women who are planning a pregnancy should discuss stopping weight-loss medicines with their healthcare provider in advance. This is partly about the drug itself and partly because rapid weight loss in early pregnancy carries its own risks regardless of cause.

For women whose weight was well managed on Mounjaro and who then stop, some weight regain is likely. That does not mean treatment has failed; it reflects the biology of how these medicines work. Planning the transition with a prescriber before conception attempts begin means you can discuss what support is available during and after pregnancy. You can read more about how tirzepatide works biologically on the tirzepatide overview page.

Step 3: contraception while taking Mounjaro

Effective contraception is central to using Mounjaro safely in women of childbearing age. There is a specific pharmacological reason to pay attention here: tirzepatide slows gastric emptying, which can reduce how much of an oral contraceptive pill is absorbed into the bloodstream. MHRA guidance and UK clinical sources therefore advise adding a non-oral contraceptive method (for example condoms) for the first four weeks of starting tirzepatide and for four weeks after each dose increase. This applies specifically to the oral pill; other methods such as implants, coils or patches are not affected by gut-absorption changes in the same way.

If you are currently using the pill and considering starting Mounjaro, it is worth reading the detailed breakdown on Mounjaro and birth control before your consultation. For a closer look at how tirzepatide interacts with oral contraceptive absorption specifically, the pill absorption page covers the mechanism clearly. There is also a common question about whether Mounjaro might affect fertility more broadly; the can Mounjaro make you infertile page addresses that directly.

The general side-effect and safety profile of Mounjaro, beyond reproductive considerations, is covered in full on the Mounjaro effects page. Costs and what private treatment includes are explained on the Mounjaro UK price context page.

Step 4: what happens next if you have already been exposed

An unplanned pregnancy while taking Mounjaro is not a reason to panic, but it does require prompt action. Stop the medicine, contact your GP or midwife as soon as possible, and let them know you were taking tirzepatide and at what dose. Your healthcare team can then refer you to appropriate antenatal care and ensure your situation is documented. Eli Lilly, Mounjaro's manufacturer, operates a pregnancy exposure registry (your GP or the Patient Information Leaflet can provide details) and reporting helps build the human safety data that currently does not exist.

Because Mounjaro is a Black Triangle medicine under additional MHRA monitoring, suspected adverse effects including pregnancy exposures can also be reported via the Yellow Card scheme at yellowcard.mhra.gov.uk. These reports actively shape future prescribing guidance. If you want to explore what a medically supervised weight-management plan looks like outside of pregnancy, our weight-loss treatment overview is a starting point.

Starting a family and managing weight are not competing goals, they just require careful clinical sequencing. If you would like to talk through your situation with a prescriber, start your free consultation and a GPhC-registered prescriber will review your details the same day.